- Home
- HRTX vs NGNE Comparison
HRTX vs NGNE Comparison
Compare HRTX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- NGNE
- Stock Information
- Founded
- HRTX 1983
- NGNE 2003
- Country
- HRTX United States
- NGNE United States
- Employees
- HRTX N/A
- NGNE N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- NGNE Health Care
- Exchange
- HRTX Nasdaq
- NGNE Nasdaq
- Market Cap
- HRTX 276.1M
- NGNE 325.3M
- IPO Year
- HRTX 1987
- NGNE N/A
- Fundamental
- Price
- HRTX $1.35
- NGNE $18.48
- Analyst Decision
- HRTX Strong Buy
- NGNE Strong Buy
- Analyst Count
- HRTX 2
- NGNE 7
- Target Price
- HRTX $4.50
- NGNE $41.86
- AVG Volume (30 Days)
- HRTX 2.6M
- NGNE 110.1K
- Earning Date
- HRTX 08-08-2025
- NGNE 08-11-2025
- Dividend Yield
- HRTX N/A
- NGNE N/A
- EPS Growth
- HRTX N/A
- NGNE N/A
- EPS
- HRTX N/A
- NGNE N/A
- Revenue
- HRTX $149,694,000.00
- NGNE N/A
- Revenue This Year
- HRTX $10.62
- NGNE N/A
- Revenue Next Year
- HRTX $12.99
- NGNE N/A
- P/E Ratio
- HRTX N/A
- NGNE N/A
- Revenue Growth
- HRTX 9.78
- NGNE N/A
- 52 Week Low
- HRTX $1.04
- NGNE $6.88
- 52 Week High
- HRTX $2.68
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- HRTX 36.48
- NGNE 35.93
- Support Level
- HRTX $1.33
- NGNE $19.59
- Resistance Level
- HRTX $1.43
- NGNE $20.46
- Average True Range (ATR)
- HRTX 0.07
- NGNE 1.23
- MACD
- HRTX 0.02
- NGNE -0.20
- Stochastic Oscillator
- HRTX 45.45
- NGNE 13.37
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.